Clinical Trials Browser

Phase 1/2 × Terminated × quizartinib × Clear all

NCT03735875 2024-09-19

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Phase 1/2 Terminated

8 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute